Time to reconsider blood monitoring guidance: a retrospective review of patients with psoriasis requiring discontinuation of biologic therapy

Clinical and Experimental Dermatology 2026

View at publisher
Authors: Kim Younghoon, Daniel Yi Liang Tan, Anthony Bewley, Padma Mohandas, Sarah Helen Mehrtens
DOI: 10.1093/ced/llag058
Cited by: 0
References: 5

Abstract

Regular blood monitoring is currently advocated for patients with psoriasis receiving biologic therapy because of their immunomodulatory potential. Our study presents long-term follow-up data from a large cohort of patients with psoriasis and demonstrates a low incidence of discontinuation of biologic therapy as a result of laboratory abnormalities. We discuss the potential implications of the relevant findings for future blood monitoring guidance, particularly given the growing number of patients being treated with biologics.

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Spondyloarthritis Studies and Treatments Dermatology and Skin Diseases

Publication details

Journal / source
Clinical and Experimental Dermatology
Volume
51
Issue
6
Pages
1113–1116
Publication date
31 January 2026
Language
EN